|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001758,
umls-concept:C0006610,
umls-concept:C0146224,
umls-concept:C0278689,
umls-concept:C0392747,
umls-concept:C0443172,
umls-concept:C0871261,
umls-concept:C1423594,
umls-concept:C1516213,
umls-concept:C1522690,
umls-concept:C1538046,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2346918,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-1-17
|
|
pubmed:abstractText |
To examine early changes in CA125 relative to objective response in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD) or topotecan and to compare the CA125 trends between the two chemotherapeutics.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1083-7159
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
72-8
|
|
pubmed:dateRevised |
2007-5-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17227902-Adult,
pubmed-meshheading:17227902-Aged,
pubmed-meshheading:17227902-Aged, 80 and over,
pubmed-meshheading:17227902-Antineoplastic Agents,
pubmed-meshheading:17227902-CA-125 Antigen,
pubmed-meshheading:17227902-Doxorubicin,
pubmed-meshheading:17227902-Female,
pubmed-meshheading:17227902-Humans,
pubmed-meshheading:17227902-Middle Aged,
pubmed-meshheading:17227902-Neoplasm Recurrence, Local,
pubmed-meshheading:17227902-Ovarian Neoplasms,
pubmed-meshheading:17227902-Polyethylene Glycols,
pubmed-meshheading:17227902-Retrospective Studies,
pubmed-meshheading:17227902-Topotecan,
pubmed-meshheading:17227902-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
|
|
pubmed:affiliation |
The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA. rcoleman@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase III
|
